Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022

Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease. As carcinoid tumors are rare and there are no data supporting stage migration, the aim of this study was to perform comprehensive trends analysis in addition to survival analysis over two decades.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoid Tumor Adenocarcinoma Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors SEER Database Analysis Stage

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with gastrointestinal carcinoid tumors

Exclusion criteria

patients with unknown age data

Treatment and study plan

Primary outcomes

The percent change and annual percent change for gastrointestinal carcinoids

Time frame: 2000-2022
the percent change and annual percent change for gastrointestinal carcinoids across different stage distribution at diagnosis (localized, regional, distant, unknown)

Time frame: 2000-2022

Sponsors and collaborators

Lead sponsor

Suez Canal University

Other

Registry information

Important dates

Study start: 2000
Primary completion: 2022
Study completion: 2022
First posted: Jan 5, 2026
Registry last updated: Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed